J&J Consumer Health Has Digital And Natural Drivers For ‘Above Market’ Growth
Executive Summary
OTC drug sales grew worldwide 4.4% on an operational basis to $4.34bn, with US segment driving increase. US OTC sales jumped 7.8% to reach $1.85bn and international sales grew 2.1% to $2.48bn. J&J consumer segment got a lift from mid-year addition of Zarbees.
You may also be interested in...
J&J Consumer Health More Than A Revenue Stream: Driving Development Across Segments
CEO Alex Gorsky and medtech business leader Joaquin Duato say consumers’ growing interest in self-care is influencing the firm’s work across segments. Consumer health also is driver for Healthy Lives Mission to invest $800m through 2030 to improve the health of people and the world.
Balancing Beauty Lineup With International And Regional Brands Factors In J&J Consumer Growth
While J&J benefits from “underlying strength” of its large skin care brands, it targets “regular additions of local, smaller brands,’ says global consumer business head Thibaut Mongon. Portfolio balance of international and localized brands helps it weather economic uncertainty during the COVID-19 pandemic.
J&J International Baby, Beauty Lines Could Lead Trimming 10% Of Consumer Portfolio
J&J plans to cut 10% of its consumer health portfolio, with most divestitures in the baby and beauty care segments outside the US. It plans to focus on growing “stronghold” categories of skin health and self care, including Aveeno and Tylenol.